- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00308581
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 3
Rozszerzony dostęp
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Innsbruck, Austria
-
Oberpullendorf, Austria
-
Wien, Austria
-
-
-
-
-
Bonheiden, Belgia
-
Brussels, Belgia
-
Genk, Belgia
-
Gent, Belgia
-
Kortrijk, Belgia
-
Leuven, Belgia
-
Liege, Belgia
-
Roeselare, Belgia
-
-
-
-
-
Aalborg, Dania
-
Arhus, Dania
-
Copenhagen, Dania
-
Herlev, Dania
-
-
-
-
-
Amiens, Francja
-
Clichy, Francja
-
Grenoble, Cedex 9, Francja
-
Lille, Francja
-
Montpellier, Cédex 5, Francja
-
Nice, Francja, Cedex 3
-
Paris, Francja
-
Pessac, Francja
-
Rouen, Francja
-
Toulouse, Cedex 9, Francja
-
-
-
-
-
Barcelona, Hiszpania
-
Madrid, Hiszpania
-
Oviedo, Hiszpania
-
Santiago De Compostela, Hiszpania
-
Sevilla, Hiszpania
-
Valencia, Hiszpania
-
-
-
-
-
Amsterdam, Holandia
-
Eindhoven, Holandia
-
Enschede, Holandia
-
Heerlen, Holandia
-
Leiden, Holandia
-
Terneuven, Holandia
-
Zwolle, Holandia
-
-
-
-
-
Calgary, Kanada
-
-
Alberta
-
Edmonton, Alberta, Kanada
-
-
British Columbia
-
Vancouver, British Columbia, Kanada
-
-
Ontario
-
London, Ontario, Kanada
-
Richmond, Ontario, Kanada
-
Toronto, Ontario, Kanada
-
-
-
-
-
Berlin, Niemcy
-
Hamburg, Niemcy
-
Hannover, Niemcy
-
Herne, Niemcy
-
Kiel, Niemcy
-
Leipzig, Niemcy
-
Minden, Niemcy
-
Munchen, Niemcy
-
Munich, Niemcy
-
-
-
-
-
Oslo, Norwegia
-
Tromso, Norwegia
-
-
-
-
California
-
San Francisco, California, Stany Zjednoczone
-
-
Florida
-
Gainesville, Florida, Stany Zjednoczone
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone
-
Louisville, Kentucky, Stany Zjednoczone
-
-
Louisiana
-
Baton Rouge, Louisiana, Stany Zjednoczone
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone
-
-
Minnesota
-
Rochester, Minnesota, Stany Zjednoczone
-
-
Nebraska
-
Lincoln, Nebraska, Stany Zjednoczone
-
-
New York
-
Great Neck, New York, Stany Zjednoczone
-
New York, New York, Stany Zjednoczone
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone
-
Charlotte, North Carolina, Stany Zjednoczone
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone
-
Cleveland, Ohio, Stany Zjednoczone
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone
-
Pittsburgh, Pennsylvania, Stany Zjednoczone
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone
-
-
Tennessee
-
Germantown, Tennessee, Stany Zjednoczone
-
Kingsport, Tennessee, Stany Zjednoczone
-
Nashville, Tennessee, Stany Zjednoczone
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone
-
Galveston, Texas, Stany Zjednoczone
-
Houston, Texas, Stany Zjednoczone
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stany Zjednoczone
-
-
-
-
-
Basel, Szwajcaria
-
Bern, Szwajcaria
-
Lausanne, Szwajcaria
-
-
-
-
-
Goteborg, Szwecja
-
Malmo, Szwecja
-
Orebro, Szwecja
-
Stockholm, Szwecja
-
-
-
-
-
Bari, Włochy
-
Bologna, Włochy
-
Milano, Włochy
-
Padova, Włochy
-
Palermo, Włochy
-
Roma, Włochy
-
Torino, Włochy
-
-
-
-
-
Bristol, Zjednoczone Królestwo
-
Cambridge, Zjednoczone Królestwo
-
Edinburgh, Zjednoczone Królestwo
-
London, Zjednoczone Królestwo
-
Nottingham, Zjednoczone Królestwo
-
Oxford, Zjednoczone Królestwo
-
Sheffield, Zjednoczone Królestwo
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Subjects with Crohn's Disease
- Previous treatment failure to Infliximab (intolerance and/or no response)
Exclusion Criteria:
- Obstructive intestinal strictures
- Recent bowel resection
- Proctocolectomy or total colectomy
- Current total parenteral nutrition
- Short bowel syndrome
- All concomitant diseases or pathological conditions that could interfere with Crohn's disease assessment or to be harmful for the well being of the patient
- Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Active 1
Q4W regimen - every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol |
400mg Certolizumab Pegol, Q4W, administered 4-weekly
Inne nazwy:
400mg Certolizumab Pegol, Q2W, administered 2-weekly
Inne nazwy:
placebo administered 4-weekly in Active 1
|
Eksperymentalny: Active 2
Q2W regimen - every 2 weeks: 400 mg Certolizumab Pegol |
400mg Certolizumab Pegol, Q4W, administered 4-weekly
Inne nazwy:
400mg Certolizumab Pegol, Q2W, administered 2-weekly
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Response Status With Response Defined as at Least 100 Point Decrease in Crohn's Disease Activity Score (CDAI Score) From Baseline in the Induction Phase
Ramy czasowe: Baseline to Week 6
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score) from baseline, otherwise there is a non-response. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity. |
Baseline to Week 6
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Response Status With Response Defined as at Least 100 Point Decrease in CDAI Score From Baseline in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 26
|
Response is defined as at least 100 point decrease in CDAI score from baseline.
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 26
|
Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Induction Phase
Ramy czasowe: Baseline to Week 6
|
Response is defined as at least 70 points reduction in CDAI score.
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 6
|
Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 26
|
Response is defined as at least 70 points reduction in CDAI score.
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 26
|
Remission Status With Remission Defined as CDAI Score ≤ 150 in the Induction Phase
Ramy czasowe: Week 6
|
Remission is defined as CDAI score ≤ 150.
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 6
|
Remission Status With Remission Defined as CDAI Score ≤ 150 in the Randomized Maintenance Phase
Ramy czasowe: Week 26
|
Remission is defined as CDAI score ≤ 150.
The CDAI score is used to quantify the symptoms with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 26
|
CDAI Score at Week 2 of the Induction Phase
Ramy czasowe: Week 2
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 2
|
CDAI Score at Week 4 of the Induction Phase
Ramy czasowe: Week 4
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 4
|
CDAI Score at Week 6 of the Induction Phase
Ramy czasowe: Week 6
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 6
|
CDAI Score at Week 8 in the Randomized Maintenance Phase
Ramy czasowe: Week 8
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 8
|
CDAI Score at Week 10 in the Randomized Maintenance Phase
Ramy czasowe: Week 10
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 10
|
CDAI Score at Week 12 in the Randomized Maintenance Phase
Ramy czasowe: Week 12
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 12
|
CDAI Score at Week 14 in the Randomized Maintenance Phase
Ramy czasowe: Week 14
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 14
|
CDAI Score at Week 16 in the Randomized Maintenance Phase
Ramy czasowe: Week 16
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 16
|
CDAI Score at Week 18 in the Randomized Maintenance Phase
Ramy czasowe: Week 18
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 18
|
CDAI Score at Week 20 in the Randomized Maintenance Phase
Ramy czasowe: Week 20
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 20
|
CDAI Score at Week 22 in the Randomized Maintenance Phase
Ramy czasowe: Week 22
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 22
|
CDAI Score at Week 24 in the Randomized Maintenance Phase
Ramy czasowe: Week 24
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 24
|
CDAI Score at Week 26 in the Randomized Maintenance Phase
Ramy czasowe: Week 26
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 26
|
Change From Baseline in CDAI Score at Week 2 of the Induction Phase
Ramy czasowe: Baseline to Week 2
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 2
|
Change From Baseline in CDAI Score at Week 4 of the Induction Phase
Ramy czasowe: Baseline to Week 4
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 4
|
Change From Baseline in CDAI Score at Week 6 of the Induction Phase
Ramy czasowe: Baseline to Week 6
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 6
|
Change From Baseline in CDAI Score at Week 8 in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 8
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 8
|
Change From Baseline in CDAI Score at Week 10 in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 10
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 10
|
Change From Baseline in CDAI Score at Week 12 in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 12
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 12
|
Change From Baseline in CDAI Score at Week 14 in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 14
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 14
|
Change From Baseline in CDAI Score at Week 16 in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 16
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 16
|
Change From Baseline in CDAI Score at Week 18 in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 18
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 18
|
Change From Baseline in CDAI Score at Week 20 in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 20
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 20
|
Change From Baseline in CDAI Score at Week 22 in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 22
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 22
|
Change From Baseline in CDAI Score at Week 24 in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 24
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 24
|
Change From Baseline in CDAI Score at Week 26 in the Randomized Maintenance Phase
Ramy czasowe: Baseline to Week 26
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 26
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 10
|
Remission is defined as CDAI score ≤ 150.
|
Week 10
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 12
|
Remission is defined as CDAI score ≤ 150.
|
Week 12
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 14
|
Remission is defined as CDAI score ≤ 150.
|
Week 14
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 16
|
Remission is defined as CDAI score ≤ 150.
|
Week 16
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 18
|
Remission is defined as CDAI score ≤ 150.
|
Week 18
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 20
|
Remission is defined as CDAI score ≤ 150.
|
Week 20
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 22
|
Remission is defined as CDAI score ≤ 150.
|
Week 22
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 24
|
Remission is defined as CDAI score ≤ 150.
|
Week 24
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 26
|
Remission is defined as CDAI score ≤ 150.
|
Week 26
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 10
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 10
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 12
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 12
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 14
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 14
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 16
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 16
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 18
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 18
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 20
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 20
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 22
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 22
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 24
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 24
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Ramy czasowe: Week 26
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 26
|
C - Reactive Protein (CRP) Level at Baseline (Week 0) of the Induction Phase
Ramy czasowe: Week 0
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 0
|
CRP Level at Week 2 of the Induction Phase
Ramy czasowe: Week 2
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 2
|
CRP Level at Week 4 of the Induction Phase
Ramy czasowe: Week 4
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 4
|
CRP Level at Week 6 of the Induction Phase
Ramy czasowe: Week 6
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 6
|
CRP Level at Week 8 in the Randomized Maintenance Phase
Ramy czasowe: Week 8
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 8
|
CRP Level at Week 10 in the Randomized Maintenance Phase
Ramy czasowe: Week 10 (optional measurement)
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 10 (optional measurement)
|
CRP Level at Week 12 in the Randomized Maintenance Phase
Ramy czasowe: Week 12
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 12
|
CRP Level at Week 14 in the Randomized Maintenance Phase
Ramy czasowe: Week 14 (optional measurement)
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 14 (optional measurement)
|
CRP Level at Week 16 in the Randomized Maintenance Phase
Ramy czasowe: Week 16
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 16
|
CRP Level at Week 18 in the Randomized Maintenance Phase
Ramy czasowe: Week 18 (optional measurement)
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 18 (optional measurement)
|
CRP Level at Week 20 in the Randomized Maintenance Phase
Ramy czasowe: Week 20
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 20
|
CRP Level at Week 22 in the Randomized Maintenance Phase
Ramy czasowe: Week 22 (optional measurement)
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 22 (optional measurement)
|
CRP Level at Week 24 in the Randomized Maintenance Phase
Ramy czasowe: Week 24
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 24
|
CRP Level at Week 26 in the Randomized Maintenance Phase
Ramy czasowe: Week 26
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 26
|
CRP Level at Endpoint (Last Visit) in the Randomized Maintenance Phase
Ramy czasowe: Last visit on or before Week 26
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
Endpoint is the visit when the last observation was taken, either at week 26 or at a visit before in case of early dropout.
|
Last visit on or before Week 26
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Time to Loss of Response (CDAI Score > 150 and Minimum Increase in CDAI of 70) After Week 6
Ramy czasowe: Week 6 to Week 26
|
Median time to loss of response in the maintenance period (from Kaplan-Meier analysis); range is time of first event to time of last event.
Loss of response is defined as both a CDAI score > 150 points and a minimum increase in CDAI of 70 points versus Week 6 at two consecutive visits.
|
Week 6 to Week 26
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Publikacje ogólne
- Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, Gomez-Reino J, Eberhardt E, Wolfe F, Schwartzman S, Furfaro N, Kavanaugh A. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res. 2010 Jul-Aug;38(4):1213-24. doi: 10.1177/147323001003800402.
- Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2. doi: 10.1016/j.cgh.2010.04.021. Epub 2010 May 6.
- Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011 Mar;33(5):541-50. doi: 10.1111/j.1365-2036.2010.04568.x. Epub 2011 Jan 12.
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- C87042
- Eudract number: 2005-004104-37
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Choroba Crohna
-
Bambino Gesù Hospital and Research InstituteZakończonyCiężka otyłość dziecięca (BMI > 97° szt. -według wykresów BMI Centers for Disease Control and Prevention-) | Zmienione testy czynnościowe wątroby | Nietolerancja glikemicznaWłochy
-
Spero TherapeuticsZakończonyKompleks Mycobacterium Avium | Niegruźlicze Mycobacterium Pulmonary DiseaseStany Zjednoczone
-
Janssen Pharmaceutical K.K.RekrutacyjnyOporna na leczenie Mycobacterium Avium Complex-lung Disease (MAC-LD)Tajwan, Republika Korei, Japonia
-
Adelphi Values LLCBlueprint Medicines CorporationZakończonyBiałaczka z komórek tucznych (MCL) | Agresywna mastocytoza układowa (ASM) | SM w Assoc Clonal Hema Lineage Non-mast Cell Lineage Disease (SM-AHNMD) | Tląca się mastocytoza układowa (SSM) | Indolentna układowa mastocytoza (ISM) Podgrupa ISM w pełni zatrudnionaStany Zjednoczone
Badania kliniczne na Certolizumab pegol
-
UCB PharmaWycofaneChoroba Leśniowskiego-Crohna
-
UCB PharmaZakończony
-
Atlanta Gastroenterology AssociatesUCB PharmaNieznany
-
UCB Pharma SAZakończonyChoroba CrohnaStany Zjednoczone, Australia, Austria, Białoruś, Belgia, Bułgaria, Kanada, Czechy, Dania, Estonia, Niemcy, Węgry, Izrael, Włochy, Nowa Zelandia, Norwegia, Polska, Federacja Rosyjska, Serbia, Singapur, Słowenia, Afryka Południowa, Hi... i więcej
-
UCB PharmaZakończonyReumatyzmDania, Holandia, Polska, Szwecja
-
University of WashingtonUniversity of Pennsylvania; UCB PharmaZakończonyWrzodziejące zapalenie okrężnicyStany Zjednoczone
-
UCB PharmaZakończonyChoroba CrohnaStany Zjednoczone, Francja, Włochy, Zjednoczone Królestwo, Belgia, Niemcy, Hiszpania, Szwajcaria, Kanada, Holandia, Austria, Szwecja
-
UCB PharmaZakończonyReumatyzmStany Zjednoczone, Francja, Włochy, Niemcy, Hiszpania, Kanada, Holandia